Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
a1DC + conserved HIV peptides
- Development stage
- Preclinical
- Lead developer
- University of Pittsburgh
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Peptides, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Subcutaneous, Intravenous
01
Overview
a1DC + conserved HIV peptides is an investigational immunotherapeutic product designed for the treatment or prevention of HIV infection. The therapy consists of autologous type 1-polarized dendritic cells (a1DCs) that are loaded ex vivo with highly conserved peptides derived from the human immunodeficiency virus (HIV). These dendritic cells are intended to stimulate and enhance the patient’s immune response against multiple, less variable regions of the virus, potentially overcoming issues related to viral diversity and immune escape. The approach leverages the potent antigen-presenting capabilities of type 1-polarized dendritic cells to induce robust cytotoxic T lymphocyte responses targeting conserved elements across different strains of HIV. This strategy aims to improve control over viral replication and may be used as part of therapeutic vaccination or functional cure strategies.
- Other names
- a1DC loaded with HIV peptidea-1DC loaded with HIV peptidea 1DC loaded with HIV peptide
Beyond the preview
Go deeper on a1DC + conserved HIV peptides.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on a1DC + conserved HIV peptides.